Most Read Articles
25 Aug 2015
At the Northern Pharmacists Convention cum 48th Malaysian Pharmaceutical Society Seminar 2015 held recently at Bayview Beach Hotel, Penang, Sanofi invited three distinguished speakers – Dr Khaw Chong Hui, Dr Lo Kang Shang Chit, and Professor Dr Karl-Josef Gundermann – to speak on the importance of renal protection in managing diabetic hypertension, the use of antihistamines in managing chronic urticaria (CU), and the role of essential phospholipids (EPL) in fatty liver diseases, respectively.
Roshini Claire Anthony, 07 Nov 2017

Women who are underweight, particularly in their late teens and mid-thirties, may be at risk for early menopause, a recent study found. 

16 Aug 2014

New drug applications approved by US FDA as of 15-30 Aug which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

17 May 2017
The high-concentration capsaicin patch shows promise in the management of painful diabetic peripheral neuropathy (PDPN), with an effect that is similar to that observed with oral agents but offering systemic tolerability benefits, according to a network meta-analysis.

Can linoleic acid avert onset of type 2 diabetes?

Jairia Dela Cruz
07 Dec 2017

Long-term dietary intake of linoleic acid may help prevent the development of type 2 diabetes (T2D), with the linoleic acid metabolite arachidonic acid having no harmful effects, according to a meta-analysis of 20 prospective cohort studies.

The analysis involved 39,740 adults without T2D at baseline, among whom 4,347 developed T2D during 366,073 person-years of follow-up. Pooled data on biomarkers of linoleic and arachidonic acid revealed an inverse association between baseline linoleic acid levels and incidence of T2D overall (risk ratio [RR] per interquintile range, 0.65; 95 percent CI, 0.60 to 0.72; p<0.0001). [Lancet Diabetes Endocrinol 2017;5;965–974]

“Associations between linoleic acid biomarkers and T2D were generally similar in different lipid compartments, including phospholipids, plasma, cholesterol esters and adipose tissue,” the authors noted.

In contrast, baseline levels of arachidonic acid were not significantly associated with the risk of incident T2D overall (RR per interquintile range, 0.96; 0.88 to 1.05; p=0.38) or in individual lipid compartments, with the exception of plasma (RR per interquintile range, 0.73; 0.62 to 0.86; p=0.0003).

Of note, prespecified potential sources of heterogeneity, such as age, body mass index, sex, race, aspirin use and omega-3 polyunsaturated fatty acid (PUFA) levels, among others, did not significantly modify the associations observed between linoleic and arachidonic acid levels and incident T2D.

“Our analysis provides novel findings that, when combined with in-vitro experimental and shorter-term interventions for metabolic risk factors, linoleic acid has an additional role for prevention of T2D in healthy populations,” the authors said.

When incorporated into phospholipids, linoleic acid is said to alter membrane fluidity and potentially modulate insulin receptor activity. This is supported by previous studies reporting that dietary PUFAs improve glycaemia, insulin resistance and insulin secretion capacity compared with carbohydrate, saturated fat and even monounsaturated fat for some endpoints. [Diabetologia 2015;58:282–89; PLoS Med 2016;13:e1002087]

“Because dietary linoleic acid intake correlates with levels of circulating and tissue linoleic acid, our biomarker-based findings extend and expand these previous results by providing evidence that linoleic acid might have long-term benefits for preventing the onset of T2D, supporting clinical recommendations to increase dietary intake of linoleic acid-rich vegetable oils,” the authors pointed out.

The established benefits of PUFAs for blood cholesterol levels and glucose-insulin homoeostasis, notwithstanding, some scientists maintain that omega-6 PUFA is harmful for health. Such harm is postulated to involve the conversion of linoleic acid to arachidonic acid, which is considered proinflammatory and potentially detrimental to glucose metabolism, weight regulation and eating behaviour. [Prostaglandins Other Lipid Mediat 2016; 125: 90–99]

However, “our findings do not corroborate concerns about potential harmful effects of arachidonic acid,” the authors said. “This is consistent with a recent systematic review reporting that levels of the biomarker arachidonic acid were associated with lower incidence of coronary heart disease.” [Ann Intern Med 2014; 160: 398–406]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
25 Aug 2015
At the Northern Pharmacists Convention cum 48th Malaysian Pharmaceutical Society Seminar 2015 held recently at Bayview Beach Hotel, Penang, Sanofi invited three distinguished speakers – Dr Khaw Chong Hui, Dr Lo Kang Shang Chit, and Professor Dr Karl-Josef Gundermann – to speak on the importance of renal protection in managing diabetic hypertension, the use of antihistamines in managing chronic urticaria (CU), and the role of essential phospholipids (EPL) in fatty liver diseases, respectively.
Roshini Claire Anthony, 07 Nov 2017

Women who are underweight, particularly in their late teens and mid-thirties, may be at risk for early menopause, a recent study found. 

16 Aug 2014

New drug applications approved by US FDA as of 15-30 Aug which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

17 May 2017
The high-concentration capsaicin patch shows promise in the management of painful diabetic peripheral neuropathy (PDPN), with an effect that is similar to that observed with oral agents but offering systemic tolerability benefits, according to a network meta-analysis.